Trial Profile
Observational, Multicenter, Cross-sectional, Observational Study to Evaluate the Effectiveness in Routine Clinical Practice of Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) for the Treatment of Acromegaly: SOMACROL Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Lanreotide (Primary)
- Indications Acromegaly
- Focus Therapeutic Use
- Acronyms SOMACROL
- Sponsors Ipsen
- 27 Oct 2017 Status changed from recruiting to completed.
- 25 Jul 2017 Planned number of patients changed from 150 to 100.
- 25 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Sep 2017.